Inclusion Criteria:

- Adult patients >/=18 years of age

- Metastatic HER2 positive breast cancer

- ECOG performance status 0 or 1

- Disease progression during or following trastuzumab-based therapy for 1st line
metastatic breast cancer (trastuzumab must have been part of the last prior treatment
regimen)

- Prior treatment with taxane-containing regimen

- LVEF >/=50 percent

- For women of childbearing potential agreement to use highly effective non-hormonal
form of contraception or two effective forms of non-hormonal contraception by patient
and/or partner. Contraception must continue for duration of study treatment and for
at least 6 months after last dose of study drug treatment

Exclusion Criteria:

- Prior treatment with pertuzumab or capecitabine

- Concurrent treatment with other experimental drug

- Concurrent immunotherapy or anticancer hormonal therapy

- Serious concurrent disease (e.g. active infection, uncontrolled hypertension,
cardiovascular disease)

- CNS metastases, which are not well controlled

- History of exposure to anthracycline cumulative dose equivalent to 360mg/m2
doxorubicin

- History of congestive heart failure of any New York Heart Association criteria, or
serious cardiac arrhythmia requiring treatment

- History of myocardial infarction within 6 months prior to randomization

- History of LVEF decline to below 50% during or after prior trastuzumab therapy or
other cardiac toxicity during previous trastuzumab treatment that necessitated
discontinuation of trastuzumab